BI 1703880
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BI 1703880, covering 2025-12-17 to 2025-12-17. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) [Phase 1]